ID   VGFR3_HUMAN             Reviewed;        1298 AA.
AC   P35916;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 2.
DT   02-NOV-2010, entry version 126.
DE   RecName: Full=Vascular endothelial growth factor receptor 3;
DE            Short=VEGFR-3;
DE            EC=2.7.10.1;
DE   AltName: Full=Fms-like tyrosine kinase 4;
DE            Short=FLT-4;
DE   AltName: Full=Tyrosine-protein kinase receptor FLT4;
DE   Flags: Precursor;
GN   Name=FLT4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=93007958; PubMed=1327515;
RA   Pajusola K., Aprelikova O., Korhonen J., Kaipainen A., Pertovaara L.,
RA   Alitalo R., Alitalo K.;
RT   "FLT4 receptor tyrosine kinase contains seven immunoglobulin-like
RT   loops and is expressed in multiple human tissues and cell lines.";
RL   Cancer Res. 52:5738-5743(1992).
RN   [2]
RP   ERRATUM.
RA   Pajusola K., Aprelikova O., Korhonen J., Kaipainen A., Pertovaara L.,
RA   Alitalo R., Alitalo K.;
RL   Cancer Res. 53:3845-3845(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1319394; DOI=10.1016/0888-7543(92)90277-Y;
RA   Galland F., Karamysheva A., Mattei M.-G., Rosnet O., Marchetto S.,
RA   Birnbaum D.;
RT   "Chromosomal localization of FLT4, a novel receptor-type tyrosine
RT   kinase gene.";
RL   Genomics 13:475-478(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS GLN-890 AND HIS-1146.
RC   TISSUE=Placenta;
RX   MEDLINE=93241723; PubMed=8386825;
RA   Galland F., Karamysheva A., Pebusque M.-J., Borg J.-P., Rottapel R.,
RA   Dubreuil P., Rosnet O., Birnbaum D.;
RT   "The FLT4 gene encodes a transmembrane tyrosine kinase related to the
RT   vascular endothelial growth factor receptor.";
RL   Oncogene 8:1233-1240(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=96312526; PubMed=8700872; DOI=10.1073/pnas.93.5.1988;
RA   Lee J., Gray A., Yuan J., Luoh S.-M., Avraham H., Wood W.I.;
RT   "Vascular endothelial growth factor-related protein: a ligand and
RT   specific activator of the tyrosine kinase receptor Flt4.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:1988-1992(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 761-1190.
RX   MEDLINE=92119639; PubMed=1310071;
RA   Aprelikova O., Pajusola K., Partanen J., Armstrong E., Alitalo R.,
RA   Bailey S.K., McMahon J., Wasmuth J., Huebner K., Alitalo K.;
RT   "FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-
RT   qter.";
RL   Cancer Res. 52:746-748(1992).
RN   [7]
RP   PROTEIN SEQUENCE OF 25-39.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally
RT   verified cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [8]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-527, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1063 AND TYR-1068, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [10]
RP   VARIANT LMPH1A LEU-1114.
RX   PubMed=9817924; DOI=10.1093/hmg/7.13.2073;
RA   Ferrell R.E., Levinson K.L., Esman J.H., Kimak M.A., Lawrence E.C.,
RA   Barmada M.M., Finegold D.N.;
RT   "Hereditary lymphedema: evidence for linkage and genetic
RT   heterogeneity.";
RL   Hum. Mol. Genet. 7:2073-2078(1998).
RN   [11]
RP   INVOLVEMENT IN LMPH1A, AND CHARACTERIZATION OF VARIANT LMPH1A
RP   ARG-1035.
RX   PubMed=10856194; DOI=10.1086/303019;
RA   Irrthum A., Karkkainen M.J., Devriendt K., Alitalo K., Vikkula M.;
RT   "Congenital hereditary lymphedema caused by a mutation that
RT   inactivates VEGFR3 tyrosine kinase.";
RL   Am. J. Hum. Genet. 67:295-301(2000).
RN   [12]
RP   VARIANTS LMPH1A ARG-857; PRO-1041; PRO-1044 AND LEU-1114, VARIANT
RP   SER-641, AND CHARACTERIZATION OF VARIANTS.
RX   PubMed=10835628; DOI=10.1038/75997;
RA   Karkkainen M.J., Ferrell R.E., Lawrence E.C., Kimak M.A.,
RA   Levinson K.L., McTigue M.A., Alitalo K., Finegold D.N.;
RT   "Missense mutations interfere with VEGFR-3 signalling in primary
RT   lymphoedema.";
RL   Nat. Genet. 25:153-159(2000).
RN   [13]
RP   VARIANTS JUVENILE HEMANGIOMA SER-954 AND SER-1137, AND VARIANTS
RP   ALA-494; GLN-890 AND HIS-1146.
RX   PubMed=11807987; DOI=10.1002/gcc.10028;
RA   Walter J.W., North P.E., Waner M., Mizeracki A., Blei F.,
RA   Walker J.W.T., Reinisch J.F., Marchuk D.A.;
RT   "Somatic mutation of vascular endothelial growth factor receptors in
RT   juvenile hemangioma.";
RL   Genes Chromosomes Cancer 33:295-303(2002).
RN   [14]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASP-149; CYS-378; ALA-494; SER-527;
RP   SER-641; TYR-868; ILE-1010; GLN-1031; ASN-1049; GLN-1075 AND HIS-1146.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Receptor for VEGFC. Has a tyrosine-protein kinase
CC       activity.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- INTERACTION:
CC       P35968:KDR; NbExp=1; IntAct=EBI-1005467, EBI-1005487;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- TISSUE SPECIFICITY: Placenta, lung, heart, and kidney, does not
CC       seem to be expressed in pancreas and brain.
CC   -!- DISEASE: Defects in FLT4 are the cause of lymphedema hereditary
CC       type 1A (LMPH1A) [MIM:153100]; also known as Nonne-Milroy
CC       lymphedema or Milroy disease. Hereditary lymphedema is a chronic
CC       disabling condition which results in swelling of the extremities
CC       due to altered lymphatic flow. Patients with lymphedema suffer
CC       from recurrent local infections and physical impairment.
CC   -!- DISEASE: Note=Defects in FLT4 are found in juvenile hemangioma.
CC       Juvenile hemangiomas are the most common tumors of infancy,
CC       occurring as many as 10% of all births. These benign vascular
CC       lesions enlarge rapidly during the first year of life by
CC       hyperplasia of endothelial cells and attendant pericytes, and then
CC       spontaneously involute over a period of years, leaving loose
CC       fibrofatty tissue.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC   -!- SIMILARITY: Contains 7 Ig-like C2-type (immunoglobulin-like)
CC       domains.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA48290.1; Type=Erroneous initiation;
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/FLT4";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=FLT4 entry;
CC       URL="http://en.wikipedia.org/wiki/FLT4";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X69878; CAA49505.1; -; mRNA.
DR   EMBL; U43143; AAA85215.1; -; mRNA.
DR   EMBL; X68203; CAA48290.1; ALT_INIT; mRNA.
DR   IPI; IPI00337568; -.
DR   PIR; A48999; A48999.
DR   RefSeq; NP_002011.2; -.
DR   RefSeq; NP_891555.2; -.
DR   UniGene; Hs.646917; -.
DR   ProteinModelPortal; P35916; -.
DR   SMR; P35916; 28-549, 240-764, 827-1179.
DR   DIP; DIP-5739N; -.
DR   IntAct; P35916; 2.
DR   STRING; P35916; -.
DR   PhosphoSite; P35916; -.
DR   PRIDE; P35916; -.
DR   Ensembl; ENST00000393347; ENSP00000377016; ENSG00000037280.
DR   GeneID; 2324; -.
DR   KEGG; hsa:2324; -.
DR   UCSC; uc003mlz.2; human.
DR   CTD; 2324; -.
DR   GeneCards; GC05M179962; -.
DR   H-InvDB; HIX0032025; -.
DR   HGNC; HGNC:3767; FLT4.
DR   HPA; CAB000099; -.
DR   MIM; 136352; gene.
DR   MIM; 153100; phenotype.
DR   Orphanet; 2416; Congenital lymphedema.
DR   PharmGKB; PA28183; -.
DR   eggNOG; prNOG13822; -.
DR   HOVERGEN; HBG053432; -.
DR   BRENDA; 2.7.10.1; 247.
DR   Pathway_Interaction_DB; vegfr1_2_pathway; Signaling events mediated by VEGFR1 and VEGFR2.
DR   Pathway_Interaction_DB; lymphangiogenesis_pathway; VEGFR3 signaling in lymphatic endothelium.
DR   Reactome; REACT_12529; Signaling by VEGF.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB01268; Sunitinib.
DR   NextBio; 9433; -.
DR   ArrayExpress; P35916; -.
DR   Bgee; P35916; -.
DR   CleanEx; HS_FLT4; -.
DR   Genevestigator; P35916; -.
DR   GermOnline; ENSG00000037280; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019838; F:growth factor binding; IEA:InterPro.
DR   GO; GO:0005021; F:vascular endothelial growth factor receptor...; IDA:MGI.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IGI:MGI.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; IEA:InterPro.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR020721; Tyr_kinase_VEGF3_rcpt.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   InterPro; IPR001824; Tyr_prot_kinase_rcpt_3_CS.
DR   InterPro; IPR009137; Tyr_prot_kinase_VEGFR3_rcpt_N.
DR   InterPro; IPR009134; Tyr_prot_kinase_VEGFR_rcpt_N.
DR   Gene3D; G3DSA:2.60.40.10; Ig-like_fold; 9.
DR   PANTHER; PTHR23256:SF224; Tyr_kinase_VEGF3_rcpt; 1.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PRINTS; PR01832; VEGFRECEPTOR.
DR   PRINTS; PR01835; VEGFRECEPTR3.
DR   SMART; SM00409; IG; 4.
DR   SMART; SM00408; IGc2; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50835; IG_LIKE; 6.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Glycoprotein; Immunoglobulin domain;
KW   Kinase; Membrane; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Receptor; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1     24
FT   CHAIN        25   1298       Vascular endothelial growth factor
FT                                receptor 3.
FT                                /FTId=PRO_0000016776.
FT   TOPO_DOM     25    775       Extracellular (Potential).
FT   TRANSMEM    776    797       Helical; (Potential).
FT   TOPO_DOM    798   1298       Cytoplasmic (Potential).
FT   DOMAIN       30    127       Ig-like C2-type 1.
FT   DOMAIN      151    213       Ig-like C2-type 2.
FT   DOMAIN      219    326       Ig-like C2-type 3.
FT   DOMAIN      331    415       Ig-like C2-type 4.
FT   DOMAIN      422    552       Ig-like C2-type 5.
FT   DOMAIN      555    671       Ig-like C2-type 6.
FT   DOMAIN      678    764       Ig-like C2-type 7.
FT   DOMAIN      845   1173       Protein kinase.
FT   NP_BIND     851    859       ATP (By similarity).
FT   ACT_SITE   1037   1037       Proton acceptor (By similarity).
FT   BINDING     879    879       ATP (By similarity).
FT   MOD_RES    1063   1063       Phosphotyrosine.
FT   MOD_RES    1068   1068       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   CARBOHYD     33     33       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    104    104       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    166    166       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    251    251       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    299    299       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    411    411       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    515    515       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    527    527       N-linked (GlcNAc...).
FT   CARBOHYD    594    594       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    683    683       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    690    690       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    758    758       N-linked (GlcNAc...) (Potential).
FT   DISULFID     51    111       Potential.
FT   DISULFID    158    206       Potential.
FT   DISULFID    252    310       Potential.
FT   DISULFID    445    534       Potential.
FT   DISULFID    578    653       Potential.
FT   DISULFID    699    751       Potential.
FT   VARIANT     149    149       N -> D (in dbSNP:rs34221241).
FT                                /FTId=VAR_042062.
FT   VARIANT     378    378       R -> C (in a renal clear cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_042063.
FT   VARIANT     494    494       T -> A (in dbSNP:rs307826).
FT                                /FTId=VAR_018407.
FT   VARIANT     527    527       N -> S (in dbSNP:rs35874891).
FT                                /FTId=VAR_034379.
FT   VARIANT     641    641       P -> S (in dbSNP:rs55667289).
FT                                /FTId=VAR_018408.
FT   VARIANT     857    857       G -> R (in LMPH1A; loss of kinase
FT                                activity).
FT                                /FTId=VAR_018409.
FT   VARIANT     868    868       H -> Y (in dbSNP:rs35171798).
FT                                /FTId=VAR_042064.
FT   VARIANT     890    890       H -> Q (in dbSNP:rs448012).
FT                                /FTId=VAR_018410.
FT   VARIANT     954    954       P -> S (in juvenile hemangioma;
FT                                dbSNP:rs34255532).
FT                                /FTId=VAR_018411.
FT   VARIANT    1010   1010       T -> I (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_042065.
FT   VARIANT    1031   1031       R -> Q (in dbSNP:rs56082504).
FT                                /FTId=VAR_042066.
FT   VARIANT    1035   1035       H -> R (in LMPH1A; loss of kinase
FT                                activity).
FT                                /FTId=VAR_018412.
FT   VARIANT    1041   1041       R -> P (in LMPH1A; loss of kinase
FT                                activity).
FT                                /FTId=VAR_018413.
FT   VARIANT    1044   1044       L -> P (in LMPH1A; loss of kinase
FT                                activity).
FT                                /FTId=VAR_018414.
FT   VARIANT    1049   1049       D -> N (in dbSNP:rs56310180).
FT                                /FTId=VAR_042067.
FT   VARIANT    1075   1075       R -> Q.
FT                                /FTId=VAR_042068.
FT   VARIANT    1114   1114       P -> L (in LMPH1A; loss of kinase
FT                                activity).
FT                                /FTId=VAR_018415.
FT   VARIANT    1137   1137       P -> S (in juvenile hemangioma).
FT                                /FTId=VAR_018416.
FT   VARIANT    1146   1146       R -> H (in dbSNP:rs1130379).
FT                                /FTId=VAR_018417.
FT   CONFLICT     24     24       G -> D (in Ref. 4; CAA49505).
FT   CONFLICT    745    745       R -> P (in Ref. 4; CAA49505).
FT   CONFLICT    752    753       NA -> RP (in Ref. 4; CAA49505).
FT   CONFLICT   1128   1128       L -> V (in Ref. 4; CAA49505).
FT   CONFLICT   1164   1164       E -> D (in Ref. 4; CAA49505).
SQ   SEQUENCE   1298 AA;  145599 MW;  3DC469ED3CB8B3B1 CRC64;
     MQRGAALCLR LWLCLGLLDG LVSGYSMTPP TLNITEESHV IDTGDSLSIS CRGQHPLEWA
     WPGAQEAPAT GDKDSEDTGV VRDCEGTDAR PYCKVLLLHE VHANDTGSYV CYYKYIKARI
     EGTTAASSYV FVRDFEQPFI NKPDTLLVNR KDAMWVPCLV SIPGLNVTLR SQSSVLWPDG
     QEVVWDDRRG MLVSTPLLHD ALYLQCETTW GDQDFLSNPF LVHITGNELY DIQLLPRKSL
     ELLVGEKLVL NCTVWAEFNS GVTFDWDYPG KQAERGKWVP ERRSQQTHTE LSSILTIHNV
     SQHDLGSYVC KANNGIQRFR ESTEVIVHEN PFISVEWLKG PILEATAGDE LVKLPVKLAA
     YPPPEFQWYK DGKALSGRHS PHALVLKEVT EASTGTYTLA LWNSAAGLRR NISLELVVNV
     PPQIHEKEAS SPSIYSRHSR QALTCTAYGV PLPLSIQWHW RPWTPCKMFA QRSLRRRQQQ
     DLMPQCRDWR AVTTQDAVNP IESLDTWTEF VEGKNKTVSK LVIQNANVSA MYKCVVSNKV
     GQDERLIYFY VTTIPDGFTI ESKPSEELLE GQPVLLSCQA DSYKYEHLRW YRLNLSTLHD
     AHGNPLLLDC KNVHLFATPL AASLEEVAPG ARHATLSLSI PRVAPEHEGH YVCEVQDRRS
     HDKHCHKKYL SVQALEAPRL TQNLTDLLVN VSDSLEMQCL VAGAHAPSIV WYKDERLLEE
     KSGVDLADSN QKLSIQRVRE EDAGRYLCSV CNAKGCVNSS ASVAVEGSED KGSMEIVILV
     GTGVIAVFFW VLLLLIFCNM RRPAHADIKT GYLSIIMDPG EVPLEEQCEY LSYDASQWEF
     PRERLHLGRV LGYGAFGKVV EASAFGIHKG SSCDTVAVKM LKEGATASEH RALMSELKIL
     IHIGNHLNVV NLLGACTKPQ GPLMVIVEFC KYGNLSNFLR AKRDAFSPCA EKSPEQRGRF
     RAMVELARLD RRRPGSSDRV LFARFSKTEG GARRASPDQE AEDLWLSPLT MEDLVCYSFQ
     VARGMEFLAS RKCIHRDLAA RNILLSESDV VKICDFGLAR DIYKDPDYVR KGSARLPLKW
     MAPESIFDKV YTTQSDVWSF GVLLWEIFSL GASPYPGVQI NEEFCQRLRD GTRMRAPELA
     TPAIRRIMLN CWSGDPKARP AFSELVEILG DLLQGRGLQE EEEVCMAPRS SQSSEEGSFS
     QVSTMALHIA QADAEDSPPS LQRHSLAARY YNWVSFPGCL ARGAETRGSS RMKTFEEFPM
     TPTTYKGSVD NQTDSGMVLA SEEFEQIESR HRQESGFR
//
